NCT04923152

Effective Dose of Statin Post PCI

Effects of High- or Moderate-Dose Statin on 1-Year Major Adverse Cardiovascular Events (MACE) Post Percutaneous Coronary Interventions

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 582 (actual)
• Sponsor: Shiraz University of Medical Sciences · Academic / Other
• Sex: All
• Age: 52 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

In this study post coronary stenting patients, were enrolled to receive moderate dose versus high dose statin for 1 year, and the result of major adverse cardiovascular events were recorded

Detailed description

In this randomized double-blind clinical trial, the study population was all patients with a recent history of PCI who referred to the professor kojuri cardiovascular clinic for the first post-procedure visit. In the first visit, patients were randomly divided into two groups Both groups were treated with Rosuvastatin 40 mg as high potency statin for one month after PCI. In the first group, after one month, the statin level changed to Rosuvastatin 5 mg daily (moderate intensity). In the second group, 40 mg of Rosuvastatin was continued for one year. Then, the participants were evaluated in terms of MACEs, including any hospitalization due to acute coronary syndrome, as well as history of stroke and myocardial Infarction, subsequent unplanned revascularization and cardiac death. The HS-CRP also checked between two groups

Conditions

• Statin Dose

Interventions

Type	Name	Description
DRUG	moderate statin dose	5 mg rosuvastatin per day
DRUG	high dose statin	40 mg rosuvastatin per day

Timeline

• Start date: 2020-01-01
• Primary completion: 2021-01-01
• Completion: 2021-04-01
• First posted: 2021-06-11
• Last updated: 2021-06-11

Locations

1 site across 1 country: Iran